Research Article

You have full text access to this OnlineOpen article

Contribution of activin receptor–like kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts

  1. Yunliang Chen1,
  2. Xu Shi-Wen1,
  3. Mark Eastwood2,
  4. Carol M. Black1,
  5. Christopher P. Denton1,‡,
  6. Andrew Leask1,†,‡,*,
  7. David J. Abraham1,‡

Article first published online: 30 MAR 2006

DOI: 10.1002/art.21725

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 4, pages 1309–1316, April 2006

Additional Information

How to Cite

Chen, Y., Shi-Wen, X., Eastwood, M., Black, C. M., Denton, C. P., Leask, A. and Abraham, D. J. (2006), Contribution of activin receptor–like kinase 5 (transforming growth factor β receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis & Rheumatism, 54: 1309–1316. doi: 10.1002/art.21725

Author Information

  1. 1

    Royal Free and University College Medical School, London, UK

  2. 2

    University of Westminster, London, UK

  1. †

    University of Western Ontario, London, Ontario, Canada

  1. ‡

    Drs. Denton, Leask, and Abraham contributed equally to this work.

*Canadian Institute of Health Research, Centre of Skeletal Development and Remodeling, Division of Oral Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, Dental Sciences Building, London, Ontario N6A 5C1, Canada

Publication History

  1. Issue published online: 30 MAR 2006
  2. Article first published online: 30 MAR 2006
  3. Manuscript Accepted: 19 DEC 2005
  4. Manuscript Received: 2 SEP 2005

Funded by

  • Scleroderma Foundation
  • Scleroderma Society
  • Arthritis Research Campaign
  • Raynaud's and Scleroderma Association Trust
  • British Heart Foundation
  • Welton Foundation
  • Canadian Institutes of Health Research. Grant Number: MOP-77603
  • University of Western Ontario

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (513K)

REFERENCES

  • 1
    Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma: collagen. Rheum Dis Clin North Am 1996; 22: 647–74.
  • 2
    Krieg T, Heckmann M. Regulatory mechanisms of fibroblast activity. Recenti Prog Med 1989; 80: 594–8.
  • 3
    Turck CW, Dohlman JG, Goetzl EJ. Immunological mediators of wound healing and fibrosis. J Cell Physiol Suppl 1987; 5: 89–93.
    Direct Link:
  • 4
    Leask A, Abraham DJ. TGFβ signaling and the fibrotic response. FASEB J 2004; 18: 816–27.
  • 5
    Denton CP, Abraham DJ. Transgenic analysis of scleroderma: understanding key pathogenic events in vivo. Autoimmun Rev 2004; 3: 285–93.
  • 6
    Nedelec B, Ghahary A, Scott PG, Tredget EE. Control of wound contraction: basic and clinical features. Hand Clin 2000; 16: 289–302.
  • 7
    LeRoy EC, Trojanowska MI, Smith EA. Cytokines and human fibrosis. Eur Cytokine Netw 1990; 1: 215–9.
  • 8
    Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001; 276: 17058–62.
  • 9
    Grinnell F, Ho CH. Transforming growth factor β stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp Cell Res 2002; 273: 248–55.
  • 10
    Black CM. Scleroderma: clinical aspects. J Intern Med 1993; 234: 115–8.
    Direct Link:
  • 11
    Korn JH. Scleroderma: a treatable disease. Cleve Clin J Med 2003; 70: 954.
  • 12
    Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf–mediated negative regulation of TGFβ signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253–64.
  • 13
    Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of transforming growth factor β signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum 2002; 46: 1857–65.
    Direct Link:
  • 14
    Pannu J, Gore-Hyer E, Yamanaka M, Smith EA, Rubinchik S, Dong JY, et al. An increased transforming growth factor β receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor β receptor type II in scleroderma. Arthritis Rheum 2004; 50: 1566–77.
    Direct Link:
  • 15
    Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65–74.
  • 16
    Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, et al. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005; 171: 889–98.
  • 17
    Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001; 276: 10594–601.
  • 18
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581–90.
    Direct Link:
  • 19
    Denton CP, Lindahl GE, Khan K, Shi-wen X, Ong VH, Gaspar NJ, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-β receptor (TβRIIΔk). J Biol Chem 2005; 280: 16053–65.
  • 20
    Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954–61.
  • 21
    Chen Y, Abraham DJ, Shi-wen X, Pearson JD, Black CM, Lyons KM, et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell 2004; 15: 5635–46.
  • 22
    Shi-wen X, Chen Y, Denton CP, Eastwood M, Renzoni E, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 2707–19.
  • 23
    LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880–9.
  • 24
    Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor α suppresses the induction of connective tissue growth factor by transforming growth factor-β in normal and scleroderma fibroblasts. J Biol Chem 2000; 275: 15220–5.
  • 25
    Holmes A, Abraham DJ, Chen Y, Denton C, Shi-wen X, Black CM, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003; 278: 41728–33.
  • 26
    Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 2003; 14: 538–46.
  • 27
    Meshel AS, Wei Q, Adelstein RS, Sheetz MP. Basic mechanism of three-dimensional collagen fibre transport by fibroblasts. Nat Cell Biol 2005; 7: 157–64.
  • 28
    Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13: 505–11.
  • 29
    Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 2004; 14: 241–9.
  • 30
    McWhirter A, Colosetti P, Rubin K, Miyazono K, Black C. Collagen type I is not under autocrine control by transforming growth factor-β1 in normal and scleroderma fibroblasts Lab Invest 1994; 71: 885–94.
  • 31
    Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001; 44: 474–80.
    Direct Link:
  • 32
    Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 2002; 99: 3908–13.
  • 33
    Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003; 48: 1964–78.
    Direct Link:
  • 34
    Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J. Selective inhibition of activin receptor–like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts. Arthritis Rheum 2004; 50: 4008–21.
    Direct Link:
  • 35
    Subramanian SV, Polikandriotis JA, Kelm RJ Jr, David JJ, Orosz CG, Strauch AR. Induction of vascular smooth muscle α-actin gene transcription in transforming growth factor β1-activated myofibroblasts mediated by dynamic interplay between the Pur repressor proteins and Sp1/Smad coactivators. Mol Biol Cell 2004; 15: 4532–43.
View Full Article (HTML) Get PDF (513K)